Investigational drug · Phase 2
BMS-986213
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
14
Any phase or sponsor naming "BMS-986213"
First trial start
2021
Nov 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986213", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986213" as an intervention, largest first.
- Pan Tumor Rollover StudyRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03899155 · 1,500 participants (planned) · Start Aug 9, 2019 · Primary completion Aug 25, 2029
Drug: Nivolumab; Ipilimumab and 17 more · For: Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Lynwood, California · 410 sites in all
- An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01968109 · 1,482 participants · Start Nov 5, 2013 · Primary completion May 22, 2024
Drug: Relatlimab; Nivolumab and 1 more · For: Neoplasms by Site
Sites: La Jolla, California; Aurora, Colorado; Tampa, Florida · 54 sites in all
- A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaPivotal-lookingTerminated
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05002569 · 1,093 participants · Start Oct 19, 2021 · Primary completion Dec 16, 2024
Drug: Nivolumab; Nivolumab + Relatlimab Fixed Dose Combination · For: Melanoma
Sites: Birmingham, Alabama; Springdale, Arkansas; Los Angeles, California · 184 sites in all
- A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal CancerPivotal-lookingTerminated
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05328908 · 769 participants · Start Apr 28, 2022 · Primary completion Jul 14, 2025
Drug: Nivolumab-relatlimab FDC; Regorafenib and 1 more · For: Colorectal Neoplasms
Sites: Springdale, Arkansas; Los Angeles, California; Norwich, Connecticut · 139 sites in all
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05625399 · 579 participants · Start Mar 6, 2023 · Primary completion Aug 4, 2025
Drug: Nivolumab + Relatlimab; rHuPH20 · For: Melanoma
Sites: Phoenix, Arizona; Springdale, Arkansas; Los Angeles, California · 149 sites in all
- An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) CancersPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03662659 · 274 participants · Start Oct 16, 2018 · Primary completion Aug 27, 2020
Drug: BMS-986213; Nivolumab and 3 more · For: Gastric Cancer; Cancer of the Stomach; Esophagogastric Junction
Sites: Clovis, California; Duarte, California; La Jolla, California · 79 sites in all
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaPivotal-lookingRecruiting
NYU Langone HealthAcademic, hospital or other
NCT05428007 · 105 participants (planned) · Start Feb 2, 2023 · Primary completion Mar 17, 2028
Drug: Sarilumab; Ipilimumab Injection and 1 more · For: Melanoma; Unresectable Melanoma
Sites: Los Angeles, California; Boston, Massachusetts; New York, New York · 4 sites in all
- A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06101134 · 100 participants · Start Nov 6, 2023 · Primary completion Apr 10, 2025
Drug: relatlimab+nivolumab; relatlimab+nivolumab+rHuPH20 and 2 more · For: Melanoma
Sites: Anchorage, Alaska; Phoenix, Arizona; San Francisco, California · 31 sites in all
University Health Network, TorontoAcademic, hospital or other
NCT06319196 · 54 participants (planned) · Start Nov 30, 2026 · Primary completion Feb 15, 2027
Drug: Opdualag; Nivolumab · For: Cutaneous Melanoma; Melanoma Stage IV; Mucosal Melanoma
Sites: Toronto, Canada
- A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)Active, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06708949 · 52 participants · Start Mar 20, 2025 · Primary completion Dec 15, 2028
Drug: Drugs Nivolumab; Ipilimumab and 1 more · For: Renal Cell Carcinoma, Clear Cell
Sites: Boston, Massachusetts; Durham, North Carolina; Philadelphia, Pennsylvania · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Relatlimab-nivolumab: A practical overview for dermatologists.
Mullick N, Nambudiri VE · J Am Acad Dermatol 2023
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.